Anti-Cancer Agents in Medicinal Chemistry
Title:Meet Our Editorial Board Member
Volume: 16 Issue: 3
Author(s): Michael J. Waring
Affiliation:
Export Options
About this article
Cite this article as:
Waring J. Michael, Meet Our Editorial Board Member, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/187152061603160210154723
DOI https://dx.doi.org/10.2174/187152061603160210154723 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
19
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High-accuracy Automated Diagnosis of Parkinson's Disease
Current Medical Imaging Chemoradiotherapy in Rectal Cancer
Current Drug Therapy Editorial [Hot Topic: Vaccines and Immunity (Executive Editor: Ted M. Ross)]
Current Pharmaceutical Design Bioactive Coatings for Minimally Invasive Medical Devices: Surface Modification in the Service of Medicine
Recent Patents on Biomedical Engineering (Discontinued) Editorial (Hot Topic: MiRNAs as Legitimate Targets for Cancer Therapy)
Current Drug Targets Acridine and Acridone Derivatives, Anticancer Properties and Synthetic Methods: Where Are We Now?
Anti-Cancer Agents in Medicinal Chemistry The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Review and Research Analysis of Computational Target Methods Using BioRuby and In silico Screening of Herbal Lead Compounds Against Pancreatic Cancer Using R Programming
Current Drug Metabolism Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Regulation of Sphingosine Kinase in Hematological Malignancies and Other Cancers
Anti-Cancer Agents in Medicinal Chemistry Role of Adiponectin in the Metabolic Syndrome: Current Perspectives on its Modulation as a Treatment Strategy
Current Pharmaceutical Design A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents
Current Topics in Medicinal Chemistry Multi-Target QSAR Approaches for Modeling Protein Inhibitors. Simultaneous Prediction of Activities Against Biomacromolecules Present in Gram-Negative Bacteria
Current Topics in Medicinal Chemistry In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery
Current Pharmaceutical Design Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery